Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

18.06 +1.83 (+11.28%)
Streaming Delayed Price Updated: 12:47 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024 ↗
KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
KalVista Pharma: Q2 Earnings Insights ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Recap: KalVista Pharma Q4 Earnings ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Micro-Cap Stocks That Could Be Moonshots ↗
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields. 
Via InvestorPlace
News headline image
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
From KalVista Pharmaceuticals
Via Business Wire
News headline image
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.